Edgewise Q3 net loss $40.7M ($0.39/sh); cash $563.3M; GRAND CANYON data Q4 2026

Edgewise Therapeutics, Inc.

2025-Q3 EPS reported -$1.15

Cash, equivalents and marketable securities $563.3M at Sep 30, 2025.
R&D expense $37.5M (up $3.9M QoQ) driven by EDG-15400 Phase 1 start and CIRRUS-HCM activity.
Net loss $40.7M ($0.39 per share) vs $36.1M ($0.34) prior quarter.
GRAND CANYON pivotal Becker cohort (175 enrolled) on track for topline readout in Q4 2026.
EDG-7500 CIRRUS-HCM program update expected Q4 2025; EDG-15400 Phase 1 data H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.